GlaxoSmithKline (China) Investment Co., Ltd.
GSK is a global biopharmaceutical company with the mission of "growing science, technology and talents, working together to surpass and overcome diseases." Committed to positively impact the health of 2.5 billion people over the next decade. In China, GSK (GSK) is always committed to helping improve the health, life and future of the Chinese people. Vaccines: GSK is a leading vaccine supplier in the Chinese market, committed to improving the accessibility of vaccines to Chinese patients and consumers. Our children and adult vaccines can prevent a variety of diseases: shingles, cervical cancer vaccines, and hepatitis B virus vaccines, including two dosage forms of adults and children. Prescription Drugs: GSK's prescription drug business has a rich innovative and mature product portfolio. In China, it is currently focusing on the following diseases: respiratory system, hepatitis, neurological diseases, HIV/AIDS, as well as immune system diseases including systemic lupus erythematosus and pulmonary hypertension, eosinophilic granulomatous polyangiitis (EGPA) ) Rare diseases.
GlaxoSmithKline (China) Investment Co., Ltd.
GSK is a global biopharmaceutical company with the mission of "growing science, technology and talents, working together to surpass and overcome diseases." Committed to positively impact the health of 2.5 billion people over the next decade. In China, GSK (GSK) is always committed to helping improve the health, life and future of the Chinese people. Vaccines: GSK is a leading vaccine supplier in the Chinese market, committed to improving the accessibility of vaccines to Chinese patients and consumers. Our children and adult vaccines can prevent a variety of diseases: shingles, cervical cancer vaccines, and hepatitis B virus vaccines, including two dosage forms of adults and children. Prescription Drugs: GSK's prescription drug business has a rich innovative and mature product portfolio. In China, it is currently focusing on the following diseases: respiratory system, hepatitis, neurological diseases, HIV/AIDS, as well as immune system diseases including systemic lupus erythematosus and pulmonary hypertension, eosinophilic granulomatous polyangiitis (EGPA) ) Rare diseases.
Xiamen Wantai Canghai Biological Technology Co., Ltd.
Xiamen Wantai Canghai Biotechnology Co., Ltd. is a backbone enterprise in the vaccine sector of Beijing Wantai Biopharma Co., Ltd., a well-known domestic enterprise "Yanshengtang" . It is a private technology enterprise for vaccine research and development and production in Fujian Province. Since its establishment, Xiamen Wantai Canghai Biotechnology Co., Ltd. has been focusing on deepening the vaccine industry for nearly 20 years and is committed to providing high-quality and affordable innovative vaccines for human disease prevention. Relying on the "National Infectious Disease Diagnostic Reagents and Vaccine Engineering Technology Research Center (NIDVD)" jointly established by Yangshengtang and Xiamen University, the company explored a sustainable industry-university-research model and established the world's first recombinant (Escherichia coli) virus-like particle vaccine development. Technology platform, successfully developed and launched the recombinant hepatitis E vaccine (Yikoning®) and the first domestically produced cervical cancer vaccine (Xinkoning®) and the fourth cervical cancer vaccine (Xinkoning®).
Xiamen Wantai Canghai Biological Technology Co., Ltd.
Xiamen Wantai Canghai Biotechnology Co., Ltd. is a backbone enterprise in the vaccine sector of Beijing Wantai Biopharma Co., Ltd., a well-known domestic enterprise "Yanshengtang" . It is a private technology enterprise for vaccine research and development and production in Fujian Province. Since its establishment, Xiamen Wantai Canghai Biotechnology Co., Ltd. has been focusing on deepening the vaccine industry for nearly 20 years and is committed to providing high-quality and affordable innovative vaccines for human disease prevention. Relying on the "National Infectious Disease Diagnostic Reagents and Vaccine Engineering Technology Research Center (NIDVD)" jointly established by Yangshengtang and Xiamen University, the company explored a sustainable industry-university-research model and established the world's first recombinant (Escherichia coli) virus-like particle vaccine development. Technology platform, successfully developed and launched the recombinant hepatitis E vaccine (Yikoning®) and the first domestically produced cervical cancer vaccine (Xinkoning®) and the fourth cervical cancer vaccine (Xinkoning®).
Merck Sharp & Dohme (China) Investment Co., Ltd.
For 130 years, Merck has always followed the mission of saving lives and improving lives, committed to enhancing life and bringing medicines and vaccines to overcome difficult diseases around the world. Through far-reaching policies, programs and partnerships, Merck fulfills its commitment to improve access to health care for patients and the general public. Today, Merck continues to be at the forefront of R&D, promoting its prevention and treatment of diseases that threaten human and animal health around the world—including cancer, infectious diseases such as HIV and Ebola viruses and emerging animal diseases. Merck focuses on scientific research and innovation, exploration, development, and provides drugs and vaccines that benefit millions of people around the world. Vaccines are one of the most effective areas of public health - Merck has been constantly exploring, developing and providing vaccines for disease prevention over the course of a century. Merck has played an important role in exploring, developing innovative drugs and vaccines for the treatment and prevention of infectious diseases. Merck is committed to finding solutions to severe chronic diseases such as cardiovascular disease and diabetes. Merck Animal Health is driven by research and develop, produce and sell a wide range of veterinary medicines and services. Whether it is R&D, manufacturing or sales, Merck's animal health business is a leader in the global market. Products cover the prevention, treatment and control of diseases in poultry and pets. China is a crucial part of Merck's global growth strategy. Merck China is headquartered in Shanghai, with a R&D center in Beijing and a factory in Hangzhou, realizing the integration of R&D, manufacturing and commercial operations. Merck is wholeheartedly providing high-quality innovative drugs, vaccines and services to the Chinese public to benefit Chinese society.
Merck Sharp & Dohme (China) Investment Co., Ltd.
For 130 years, Merck has always followed the mission of saving lives and improving lives, committed to enhancing life and bringing medicines and vaccines to overcome difficult diseases around the world. Through far-reaching policies, programs and partnerships, Merck fulfills its commitment to improve access to health care for patients and the general public. Today, Merck continues to be at the forefront of R&D, promoting its prevention and treatment of diseases that threaten human and animal health around the world—including cancer, infectious diseases such as HIV and Ebola viruses and emerging animal diseases. Merck focuses on scientific research and innovation, exploration, development, and provides drugs and vaccines that benefit millions of people around the world. Vaccines are one of the most effective areas of public health - Merck has been constantly exploring, developing and providing vaccines for disease prevention over the course of a century. Merck has played an important role in exploring, developing innovative drugs and vaccines for the treatment and prevention of infectious diseases. Merck is committed to finding solutions to severe chronic diseases such as cardiovascular disease and diabetes. Merck Animal Health is driven by research and develop, produce and sell a wide range of veterinary medicines and services. Whether it is R&D, manufacturing or sales, Merck's animal health business is a leader in the global market. Products cover the prevention, treatment and control of diseases in poultry and pets. China is a crucial part of Merck's global growth strategy. Merck China is headquartered in Shanghai, with a R&D center in Beijing and a factory in Hangzhou, realizing the integration of R&D, manufacturing and commercial operations. Merck is wholeheartedly providing high-quality innovative drugs, vaccines and services to the Chinese public to benefit Chinese society.
Yunnan Walvax Biotechnology Co., Ltd.
Yunnan Watson Biotechnology Co., Ltd. was established in 2001. After more than 20 years of development, it has now become a modern high-tech biopharmaceutical enterprise specializing in the research, development, production and sales of biotechnical drugs such as human vaccines. The company was listed on the Shenzhen Stock Exchange GEM in November 2010 (stock abbreviation: Watson Bio; stock code: 300142). The company is headquartered in Kunming, Yunnan, and has invested in and built a product R&D center located in Kunming National High-tech Zone, Shanghai Zhangjiang, and an industrialization base located in Yuxi National High-tech Zone, Yunnan. At the same time, vaccine industrialization technology innovation centers and industrialization bases are being built in Beijing, Guangdong, Chengdu and other places. The company's main holding companies include: Yuxi Watson Biotechnology Co., Ltd., Shanghai Zerun Biotechnology Co., Ltd., Yuxi Zerun Biotechnology Co., Ltd., Beijing Watson Innovation Biotechnology Co., Ltd., Sichuan Watson Innovation Biotechnology Co., Ltd., Guangdong Watson Pharmaceutical Technology Co., Ltd., Guangzhou Watson Health Technology Co., Ltd., etc. Currently, the total number of employees exceeds 2,300. The company's core R&D and management teams of "combining Chinese and Western" are formed by entrepreneurial teams from major national biological research institutes and overseas returnees with a background in overseas biopharmaceutical giants. The company has always adhered to the core driving force of development with technological innovation and continued to make high investments in independent research and development, and its R&D investment in operating income ranks among the top in the industry. The company and its subsidiaries are nationally recognized enterprise technology centers and national high-tech enterprises. It has successively undertaken 5 national "863" plans, undertaken 13 national "major new drug creation" special projects, and has 49 domestic authorized invention patents and 27 international PCT invention patents. After years of hard work and accumulation, the company now has two major global vaccine varieties: 13-valent pneumonia combined vaccine and HPV vaccine. Among them, the 13-valent pneumonia combination vaccine was successfully launched in April 2020, and the dual-valent HPV vaccine was approved in March 2022 and launched in May; all work on phase III clinical research of the 9-valent HPV vaccine is underway as planned. In the serum detection stage. The company has always adhered to the belief that "life is priceless and technology is unlimited", established a complete quality management system, and continuously improved and improved the production process and product quality to ensure the quality of products and services. At present, there are 8 vaccine varieties (12 product specifications), and the company's non-immunization program vaccine has completed access to 31 provinces/cities across the country and exported to 18 countries overseas. The company's AC polysaccharide vaccine has been included in the national immunization program by the Egyptian government for five consecutive years since 2018; the 13-valent pneumonia combination vaccine was exported to Morocco in May 2022. This is the first overseas export since this vaccine was launched. It is also a milestone event in the internationalization of China's vaccine industry. Watson Bio has always adhered to the principle of "making people born healthy" and integrated social responsibility into the company's development strategy and business management. Since 2018, the "People-friendly Project" has been launched in Kunming and Yuxi City. Elderly registered in the jurisdiction over 60 years old can receive the company's 23-valent pneumonia vaccine for free. Today, when the public is paying more and more attention to drug quality and safety, Watson Bio will continue to take it as its mission to strictly abide by product quality and safety, never forget its original aspiration, keep up with the pace of the times, and strive to create outstanding achievements worthy of society and the times.
Yunnan Walvax Biotechnology Co., Ltd.
Yunnan Watson Biotechnology Co., Ltd. was established in 2001. After more than 20 years of development, it has now become a modern high-tech biopharmaceutical enterprise specializing in the research, development, production and sales of biotechnical drugs such as human vaccines. The company was listed on the Shenzhen Stock Exchange GEM in November 2010 (stock abbreviation: Watson Bio; stock code: 300142). The company is headquartered in Kunming, Yunnan, and has invested in and built a product R&D center located in Kunming National High-tech Zone, Shanghai Zhangjiang, and an industrialization base located in Yuxi National High-tech Zone, Yunnan. At the same time, vaccine industrialization technology innovation centers and industrialization bases are being built in Beijing, Guangdong, Chengdu and other places. The company's main holding companies include: Yuxi Watson Biotechnology Co., Ltd., Shanghai Zerun Biotechnology Co., Ltd., Yuxi Zerun Biotechnology Co., Ltd., Beijing Watson Innovation Biotechnology Co., Ltd., Sichuan Watson Innovation Biotechnology Co., Ltd., Guangdong Watson Pharmaceutical Technology Co., Ltd., Guangzhou Watson Health Technology Co., Ltd., etc. Currently, the total number of employees exceeds 2,300. The company's core R&D and management teams of "combining Chinese and Western" are formed by entrepreneurial teams from major national biological research institutes and overseas returnees with a background in overseas biopharmaceutical giants. The company has always adhered to the core driving force of development with technological innovation and continued to make high investments in independent research and development, and its R&D investment in operating income ranks among the top in the industry. The company and its subsidiaries are nationally recognized enterprise technology centers and national high-tech enterprises. It has successively undertaken 5 national "863" plans, undertaken 13 national "major new drug creation" special projects, and has 49 domestic authorized invention patents and 27 international PCT invention patents. After years of hard work and accumulation, the company now has two major global vaccine varieties: 13-valent pneumonia combined vaccine and HPV vaccine. Among them, the 13-valent pneumonia combination vaccine was successfully launched in April 2020, and the dual-valent HPV vaccine was approved in March 2022 and launched in May; all work on phase III clinical research of the 9-valent HPV vaccine is underway as planned. In the serum detection stage. The company has always adhered to the belief that "life is priceless and technology is unlimited", established a complete quality management system, and continuously improved and improved the production process and product quality to ensure the quality of products and services. At present, there are 8 vaccine varieties (12 product specifications), and the company's non-immunization program vaccine has completed access to 31 provinces/cities across the country and exported to 18 countries overseas. The company's AC polysaccharide vaccine has been included in the national immunization program by the Egyptian government for five consecutive years since 2018; the 13-valent pneumonia combination vaccine was exported to Morocco in May 2022. This is the first overseas export since this vaccine was launched. It is also a milestone event in the internationalization of China's vaccine industry. Watson Bio has always adhered to the principle of "making people born healthy" and integrated social responsibility into the company's development strategy and business management. Since 2018, the "People-friendly Project" has been launched in Kunming and Yuxi City. Elderly registered in the jurisdiction over 60 years old can receive the company's 23-valent pneumonia vaccine for free. Today, when the public is paying more and more attention to drug quality and safety, Watson Bio will continue to take it as its mission to strictly abide by product quality and safety, never forget its original aspiration, keep up with the pace of the times, and strive to create outstanding achievements worthy of society and the times.
V505 is an experimental HPV vaccine designed to provide broader protection against multiple HPV types.
Merck & Co., Inc.
V505 is an experimental HPV vaccine designed to provide broader protection against multiple HPV types.
V504 is a research-stage HPV vaccine aimed at expanding protection against additional HPV types.
Merck & Co., Inc.
V504 is a research-stage HPV vaccine aimed at expanding protection against additional HPV types.
V501 was the development code for the initial HPV vaccine prototype, leading to the creation of Gardasil.
Merck & Co., Inc.
V501 was the development code for the initial HPV vaccine prototype, leading to the creation of Gardasil.
V502 is a research-based HPV vaccine aimed at improving efficacy and coverage against HPV-related diseases.
Merck & Co., Inc.
V502 is a research-based HPV vaccine aimed at improving efficacy and coverage against HPV-related diseases.
V506 is an experimental HPV vaccine designed to enhance immune responses against multiple HPV types.
Merck & Co., Inc.
V506 is an experimental HPV vaccine designed to enhance immune responses against multiple HPV types.
V507 is a next-generation HPV vaccine under development, targeting additional HPV types for broader protection.
Merck & Co., Inc.
V507 is a next-generation HPV vaccine under development, targeting additional HPV types for broader protection.
V508 is a research-stage HPV vaccine aimed at improving the durability and effectiveness of HPV immunization.
Merck & Co., Inc.
V508 is a research-stage HPV vaccine aimed at improving the durability and effectiveness of HPV immunization.
V520 was the development code for the original Gardasil vaccine, which protects against four HPV types.
Merck & Co., Inc.
V520 was the development code for the original Gardasil vaccine, which protects against four HPV types.
V503 is the development code for Gardasil 9, a vaccine that targets nine HPV types to prevent various cancers.
Merck & Co., Inc.
V503 is the development code for Gardasil 9, a vaccine that targets nine HPV types to prevent various cancers.
Gardasil 4 is the original version of Gardasil, protecting against four HPV types associated with cervical cancer and genital warts.
Merck & Co., Inc.
Gardasil 4 is the original version of Gardasil, protecting against four HPV types associated with cervical cancer and genital warts.
Silgard is the European brand name for Gardasil, providing protection against four types of HPV.
Merck & Co., Inc.
Silgard is the European brand name for Gardasil, providing protection against four types of HPV.
Walvax Biotechnology Co., Ltd.
Walrinvax is a domestically produced HPV vaccine in China, offering protection against HPV types 16 and
Walvax Biotechnology Co., Ltd.
Walrinvax is a domestically produced HPV vaccine in China, offering protection against HPV types 16 and
Innovax (a subsidiary of Xiamen Innovax Biotech)
Cecolin is a bivalent HPV vaccine developed in China, targeting HPV types 16 and 18, which are linked to cervical cancer.
Innovax (a subsidiary of Xiamen Innovax Biotech)
Cecolin is a bivalent HPV vaccine developed in China, targeting HPV types 16 and 18, which are linked to cervical cancer.
Gardasil 9 is an advanced version of Gardasil, offering protection against nine types of HPV, including those causing cervical, vulvar, vaginal, and anal cancers.
Merck & Co., Inc.
Gardasil 9 is an advanced version of Gardasil, offering protection against nine types of HPV, including those causing cervical, vulvar, vaginal, and anal cancers.
Cervarix is an HPV vaccine designed to prevent cervical cancer by targeting the two most common cancer-causing HPV types.
GlaxoSmithKline (GSK)
Cervarix is an HPV vaccine designed to prevent cervical cancer by targeting the two most common cancer-causing HPV types.
V511 is a research-based HPV vaccine aimed at improving coverage and efficacy against a wider range of HPV types.
Merck & Co., Inc.
V511 is a research-based HPV vaccine aimed at improving coverage and efficacy against a wider range of HPV types.
